Incyte (INCY) Capital Expenditures Growth (1y) (2011 - 2026)
Incyte (INCY) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 143.40% |
| 10 | Incyte | 23.71 Bn | 19.69 Bn | 1.17 Bn | -43.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.49% |
| Dec 31, 2025 | -138.76% |
| Sep 30, 2025 | 1,103.21% |
| Jun 30, 2025 | 177.22% |
| Mar 31, 2025 | 654.57% |
| Dec 31, 2024 | 428.70% |
| Sep 30, 2024 | -89.39% |
| Jun 30, 2024 | -69.36% |
| Mar 31, 2024 | -87.48% |
| Dec 31, 2023 | -371.03% |
| Sep 30, 2023 | 22,340.52% |
| Jun 30, 2023 | 119.98% |
| Mar 31, 2023 | -80.60% |
| Dec 31, 2022 | -115.50% |
| Sep 30, 2022 | -100.10% |
| Jun 30, 2022 | 60.53% |
| Mar 31, 2022 | -67.22% |
| Dec 31, 2021 | -32.99% |
| Sep 30, 2021 | 119.08% |
| Jun 30, 2021 | -124.82% |